Owl Therapeutics, a spin-out of Gryphon Bio, is a clinical-stage biopharmaceutical company created to develop best-in-class, artificial intelligence (AI)- and diagnostic-powered therapeutics for traumatic brain injury (TBI) and brain health. The company has rapidly built a promising, diversified pipeline of small and large molecule medicines poised to address the highly unmet needs of patients with neurodegenerative disease. Owl is led by a proven, cohesive, interdisciplinary, and internationally recognized team with deep scientific, clinical, and business experience in drug development and commercialization.
UNLOCKING WISDOM for BRAIN HEALTH
Through a partnership with Gryphon Bio, Owl's pipeline is powered by novel diagnostic blood tests for enrichment and tracking of responding patients. This de-risks and accelerates our drug discovery and development workflows, thereby increasing the likelihood of achieving successful outcomes in clinical trials and regulatory approvals.
Owl's pipeline is also powered by novel artificial intelligence (AI) and machine learning technologies to analyze vast public and private datasets-including three-dimensional chemical structures of small and large molecules as well as information from preclinical and clinical studies. This further improves our workflows and clinical trials.
Best-in-class, artificial intelligence (AI)- and diagnostic-powered therapeutics for traumatic brain injury (TBI) and brain health
OWL-1023 is a therapeutic monoclonal antibody to accelerate clearance of brain cell debris.
OWL-4130 is a therapeutic fusion protein to limit inflammation in the brain.
OWL-1975 is a small molecule therapeutic to rescue post-traumatic headache.
OWL-1410 is a small molecule therapeutic to protect neurons.